OncClubAll Oncology News
InsightsMedNews WeekOncChatsOncLive News Network®OncLive TVPeer ExchangePodcastsRapid Readouts
Conference CoverageConference Listing
Giants of Cancer CareCME/CEScientific InterchangesState of the Science Summit / IPCNational Fellows ForumWebinars
PartnersPublications
Consensus ViewpointsOncLive AppInteractive ToolsSponsored
Biomarker ConsortiumSubscribe
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
CAR T-cell Therapy
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Business Management
Pediatric Oncology
Precision Medicine in Oncology®
Sarcomas
Supportive Care
Spotlight -
  • The OncLive Insider app is live!
  • CME Opportunities
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
CAR T-cell Therapy
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Business Management
Pediatric Oncology
Precision Medicine in Oncology®
Sarcomas
Supportive Care
    • Partners
    • Publications
    • Biomarker Consortium
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Colorectal Cancer: Individualizing Treatment, Improving Outcomes

home / peer-exchange / crc-improving-outcomes
Deciding on Adjuvant Therapy in CRC

EP. 1: Deciding on Adjuvant Therapy in CRC

February 26th 2018
Duration of Adjuvant Therapy: CRC Subsets

EP. 2: Duration of Adjuvant Therapy: CRC Subsets

February 26th 2018
Managing Patients After Adjuvant Therapy

EP. 3: Managing Patients After Adjuvant Therapy

February 26th 2018
Treating Liver or Peritoneal Metastases in CRC

EP. 4: Treating Liver or Peritoneal Metastases in CRC

February 26th 2018
Early-Onset CRC: What Do We Know?

EP. 5: Early-Onset CRC: What Do We Know?

February 26th 2018
Role of Molecular Testing in CRC Management

EP. 6: Role of Molecular Testing in CRC Management

February 26th 2018
Importance of HER2 Expression in CRC

EP. 7: Importance of HER2 Expression in CRC

February 26th 2018
Left- Versus Right-Sided Tumors in CRC

EP. 8: Left- Versus Right-Sided Tumors in CRC

February 26th 2018
Frontline Antibody Selection in Metastatic CRC

EP. 9: Frontline Antibody Selection in Metastatic CRC

February 26th 2018
Maintenance and Second-Line Decisions in CRC

EP. 10: Maintenance and Second-Line Decisions in CRC

February 26th 2018
Supportive Care in Metastatic CRC

EP. 11: Supportive Care in Metastatic CRC

February 26th 2018
Immunotherapy Options in Refractory CRC

EP. 12: Immunotherapy Options in Refractory CRC

February 26th 2018
Third-Line Treatment in Refractory CRC

EP. 13: Third-Line Treatment in Refractory CRC

February 26th 2018
Dosing and Side Effect Management in Metastatic CRC

EP. 14: Dosing and Side Effect Management in Metastatic CRC

February 26th 2018
Managing Toxicities With Immunotherapy in CRC

EP. 15: Managing Toxicities With Immunotherapy in CRC

February 26th 2018
Emerging Immunotherapy Combinations in MSS CRC

EP. 16: Emerging Immunotherapy Combinations in MSS CRC

February 26th 2018
Progress in CRC Precision Medicine

EP. 17: Progress in CRC Precision Medicine

February 26th 2018
Improving Outcomes in CRC

EP. 18: Improving Outcomes in CRC

February 26th 2018

Latest Conference Coverage

First-Line Rucaparib Maintenance Reduces Progression Risk Across Prognostic Subgroups in HRD– High-Grade Ovarian Cancer

Raludotatug Deruxtecan Shows Activity in Platinum-Sensitive Ovarian Cancer

Relacorilant/Nab-Paclitaxel Is Associated With Survival Improvement in Platinum-Resistant Ovarian Cancer After Short Platinum-Free Interval

PD-L1 CPS Does Not Enrich the Efficacy of Atezolizumab/Bevacizumab and Chemo in Advanced Cervical Cancer

View More Latest Conference Coverage
Advertise
About OncLive
Editorial Board
MJH Life Sciences brands
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

Download on Apple
© 2025 MJH Life Sciences

All rights reserved.
Home
About Us
News
Contact